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A growing body of scientific evidence has linked dairy intake to a reduced type 2 diabetes
(T2D) risk. Using an evidence-based approach, we reviewed the most recent and strongest
evidence on the relationship between dairy intake and the risk of T2D. Evidence indicates
that dairy intake is significantly associated with a reduced T2D risk, and likely in a dose-
response manner. The association between low-fat dairy and T2D risk reduction appears
consistent. A beneficial impact is suggested for regular-fat dairy. The role of specific dairy
products needs to be clarified. Potential underlying mechanisms include the role of dairy
products in obesity and metabolic syndrome, as well as several dairy components, such
as calcium, vitamin D, dairy fat, and specifically trans-palmitoleic acid. To conclude, there
is strong, consistent, and accumulating evidence that dairy intake reduces the risk ofT2D.
More research is needed to better understand the role of regular-fat and specific dairy
products. Well-designed randomized controlled trials and mechanistic studies are needed
to support these findings. Efforts to translate this evidence into clinical practice and public
health guidance are needed.
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INTRODUCTION
Diabetes is a global epidemic with major health, social, and eco-
nomic implications. Over the last three decades, the prevalence
of diabetes has more than doubled, and more than 371 million
people worldwide now have diabetes (1). In 2012, diabetes was the
cause of 4.8 million deaths and the estimated health care cost of
diabetes was $471 billion worldwide (1).
Type 2 diabetes (T2D) accounts for at least 90% of all dia-
betes cases and its rates have been increasing at an alarming rate
in every country (2). Lifestyle has been identified as playing a
major role in the development and prevention of T2D. T2D usually
develops during adulthood and is associated with obesity, physical
inactivity, and unhealthy diets (2).
A growing body of scientific evidence has linked dairy prod-
ucts to a reduced risk of T2D. Potential underlying mechanisms
remain to be fully elucidated but may include a beneficial role of
dairy products in obesity and metabolic syndrome (MetS), two
important risk factors for T2D, as well as a beneficial role of cer-
tain dairy components such as calcium, vitamin D, dairy fat, and
specifically trans-palmitoleic acid.
Unfortunately, dairy products remain largely under-consumed
by all age groups. An astonishing number of Americans (more
than 80% men and 90% women) do not meet the minimum dairy
requirements of the Dietary Guidelines for Americans (DGA) (3).
A large proportion of Canadians also do not meet the minimum
daily recommendations established by Health Canada, with an
average intake for adults being 1.52 servings, which is well below
the 2–4 recommended daily servings (4). Under-consumption of
dairy products has also been reported in many other parts of the
world (5–7).
Given the increasing amount of evidence on the beneficial
role of dairy products in T2D risk reduction, ensuring optimal
dairy intake may represent an additional key strategy against this
epidemic. In this review, we aim to examine and synthesize the
scientific evidence on the association between dairy products and
T2D risk, and identify opportunities for future research. Using
a comprehensive evidence-based approach, we reviewed the evi-
dence on the relationship between dairy product intake and the
risk of T2D. Online databases were searched until March 2013
for relevant peer-reviewed articles. Priority was given to the most
recent and strongest available evidence, with a focus on meta-
analyses, randomized controlled trials (RCTs), and prospective
cohort studies.
DAIRY AND TYPE 2 DIABETES
SYSTEMATIC REVIEWS AND META-ANALYSES
Three meta-analyses of prospective cohort studies on dairy prod-
ucts and T2D were identified (Table 1). In a meta-analysis by Tong
et al. the highest dairy consumption, compared to the lowest cate-
gory, significantly reduced the risk of T2D by 14% (combined rela-
tive risk (RR) 0.86, 95% confidence interval (CI) 0.79–0.92) (8). A
significant inverse association with T2D was also observed for low-
fat dairy and yogurt. High-fat dairy and whole (regular-fat) milk
were not found to be associated with T2D. A dose-response analysis
showed a decrease of 6% in T2D risk per each additional daily serv-
ing of total dairy (RR 0.94, 95% CI 0.92–0.97). A dose-response
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Table 1 | List of studies reviewed and main findings on dairy products andT2D.
Study Main findings
SYSTEMATIC REVIEWS AND META-ANALYSES
Kratz et al. (20) Inverse association between high-fat dairy products and T2D
Tong et al. (8) T2D risk reduction by 14% for highest diary intake
Significant inverse association for low-fat dairy and yogurt
No association for high-fat dairy and whole milk
Decrease of 6% in T2D risk per each additional serving of total dairy per day
Decrease of 10% in T2D risk per each additional serving of low-fat dairy per day
Elwood et al. (9) Reduction in diabetes incidence by 4–9% for each additional daily serving of dairy products
Pittas et al. (10) Lower risk of incident T2D for the highest vs. lowest dairy intake (3–5 vs. 1.5 servings per day)
2010 Dietary Guidelines for Americans Moderate evidence indicates that dairy products is associated with a reduced risk of T2D
PROSPECTIVE COHORT STUDIES
Grantham et al. (12) Significant inverse association between the highest tertile of dairy intake and risk of diabetes among men
Significant inverse association between low-fat milk and diabetes
Louie et al. (13) No association between total dairy consumption and T2D
No association for reduced/low-fat dairy and regular-fat dairy
Significant reduction by 59% in risk of MetS with regular-fat dairy
Struijk et al. (14) No significant association between total dairy intake and T2D incidence
Beneficial effect of cheese and fermented dairy on glucose regulation indices
Soedamah-Muthu et al. (15) No significant association between total dairy consumption or specific types of dairy products and T2D
Association of fermented dairy products with reduced risk of overall mortality
Fumeron et al. (16) Inverse association between total consumption of dairy products and impaired fasting glycemia and T2D
Inverse relationship between cheese and incident metabolic syndrome
Malik et al. (17) Significantly reduced risk of T2D by 38% for highest quintile of dairy consumption during adolescence (two
servings per day)
A 43% reduction in risk of T2D with consistently high intakes of dairy products (from adolescence to adulthood)
A 25% risk reduction for the highest current consumption of dairy products (two servings per 1,000 kcal)
Sluijs et al. (18) No association between total dairy consumption and T2D
Inverse association between cheese and fermented dairy products and T2D
Mozaffarian et al. (21, 22) Significant reduction by 48–62% in risk of incident T2D with trans-palmitoleic acid
Direct association between dairy fat and trans-palmitoleic acid levels
Inverse association with risk of T2D for whole (regular-fat) dairy across all intake levels
relationship between low-fat dairy consumption and T2D was also
present, with a 10% risk reduction per additional serving (RR 0.90,
95% CI 0.85–0.95).
In their meta-analysis of four prospective cohort studies on
diabetes, Elwood et al. demonstrated that milk or dairy consump-
tion was protective against T2D (RR 0.92, 95% CI 0.86–0.97).
Each additional daily serving was significantly associated with a
reduction in diabetes incidence by 4–9% (9). In another meta-
analysis with mostly similar cohort studies, the highest vs. lowest
dairy intake (3–5 vs. 1.5 servings per day) was associated with a
lower risk of incident T2D [odds ratio (OR) 0.86, 95% CI 0.79–
0.93] (10). Furthermore, in the 2010 DGA, the Dietary Guidelines
Advisory Committee (DGAC) concluded that moderate evidence
indicates that dairy products are associated with a reduced risk of
T2D after their systematic review of literature (11).
PROSPECTIVE COHORT STUDIES
Several prospective cohort studies, published thereafter, have also
been conducted to evaluate the potential role of dairy products in
T2D prevention (Table 1).
The Australian Diabetes Obesity and Lifestyle Study (AusDiab),
a population-based, prospective survey with follow-up of 5 years,
consisting of 5,582 adults demonstrated a significant inverse asso-
ciation between the highest tertile of dairy intake and risk of
diabetes in men, after adjustment for age, sex, energy intake, and
various other clinical characteristics (adjusted OR 0.53, 95% CI
0.29–0.96) (12). Among women, a non-significant inverse associ-
ation was observed (adjusted OR 0.71, 95% CI 0.48–1.05). Among
subtypes of dairy products (low-fat milk, full-fat milk, yogurt,
cheese), only low-fat milk had a significant inverse association
with diabetes (adjusted OR 0.65, 95% CI 0.44–0.94).
Frontiers in Endocrinology | Diabetes July 2013 | Volume 4 | Article 90 | 2
Kalergis et al. Dairy and type 2 diabetes
Conversely, in another Australian prospective cohort study,
the Blue Mountains Eye Study (BMES), after adjustment for
covariates including energy intake, fiber from vegetables, dietary
glycemic load, and calcium, total dairy consumption was not
found to be associated with T2D (adjusted OR 1.50, 95% CI 0.47–
4.77) (13). No association was also observed for reduced/low-fat
dairy (adjusted OR 1.09, 95% CI 0.57–2.09), or regular-fat dairy
(adjusted OR 0.87, 95% CI 0.48–1.57), and T2D risk. However,
compared with subjects in the lowest intake quartile of regular-fat
dairy products, those in the highest quartile had a 59% lower risk
of MetS (multivariate adjusted OR 0.41, 95% CI 0.23–0.71).
A prospective analysis of the Inter99 Study, a Danish
population-based lifestyle intervention, assessed the association
between specific types of dairy products and T2D incidence.
Glucose regulation, an important underlying mechanism in the
development of T2D, was also investigated (14). No significant
association was found between total dairy intake and T2D inci-
dence (OR 0.95, 95% CI 0.86–1.06). There was also no association
between specific dairy products and T2D, but cheese and fer-
mented dairy appeared to have a beneficial effect on glucose
regulation indices. A linear inverse association was demonstrated
between cheese and 2 h plasma glucose (β=−0.048, 95% CI
−0.095 to −0.001). Fermented dairy products (cheese, yogurt,
and buttermilk) were also inversely associated with fasting plasma
glucose and hemoglobin A1c.
The Whitehall II prospective cohort study was a London-based
study of the working staff of Civil Service departments (15). Ten-
year follow-up of 4,186 participants indicated that total dairy
consumption was not significantly associated with T2D [hazard
ratio (HR) 1.30, 95% CI 0.95–1.77]. Neither high-fat dairy, low-
fat dairy, total milk, yogurt, cheese nor fermented products were
associated with T2D risk. However, fermented dairy products were
significantly associated with an inverse risk of overall mortality.
The Data from the Epidemiological Study on Insulin Resis-
tance Syndrome (DESIR) study was a prospective cohort study of
French adults, followed for 9 years (16). Adjustment was made
for potential confounders including fat intake, and analysis of
3,435 participants demonstrated that total consumption of dairy
products, excluding cheese, was inversely associated with incident
impaired fasting glycemia and T2D (adjusted OR 0.85, 95% CI
0.76–0.94). Cheese consumption was not associated with T2D
(adjusted OR 0.93, 95% CI 0.82–1.06), but an inverse relation-
ship was found between cheese and incident MetS (adjusted OR
0.82, 95% CI 0.71–0.95).
Data from 37,038 women from the Nurses’ Health Study II,
followed for 7 years, was used to evaluate whether dairy consump-
tion during adolescence was associated with the development of
T2D in adulthood (17). After adjustment for risk factors present
in adolescence, those in the highest quintile of dairy consumption
during adolescence (two servings per day) had a reduced risk of
T2D by 38%. Adjusting for risk factors present in adulthood also
showed a significant inverse association between adolescent dairy
intake and T2D (RR 0.73, 95% CI 0.54–0.97). A 43% reduction in
risk of T2D was observed for women with consistently high-dairy
intakes (from adolescence to adulthood), highlighting the impor-
tance of persistence in dairy consumption. A 25% risk reduction
was also observed for the highest current dairy consumption (two
servings per 1,000 kcal), and a 26 and 28% risk reduction with
low- and high-fat dairy, respectively.
In a nested case-cohort analysis within eight countries of the
European Prospective Investigation into Cancer and Nutrition
(EPIC) Study, consisting of a subcohort of 16,835 participants,
total dairy consumption was not associated with T2D (HR 1.01,
95% CI 0.83–1.34) (18). Both the consumption of cheese and fer-
mented dairy products (cheese, yogurt, and thick fermented milk)
were inversely associated with T2D (HR 0.88, 95% CI 0.76–1.02
and HR 0.88, 95% CI 0.78–0.99, respectively).
RANDOMIZED CONTROLLED TRIALS
To our knowledge, no RCTs to date have specifically assessed the
association between dairy products and the risk of incident T2D.
However, in a randomized crossover trial of 12 months, the con-
sumption of low-fat dairy (four servings per day) was associated
with improved insulin resistance, without adversely affecting body
weight and lipid status (19).
REGULAR/HIGH-FAT DAIRY
While the evidence appears to be relatively consistent with respect
to a beneficial role of low-fat dairy products in the prevention of
T2D, the role of regular/high-fat dairy, as well as dairy fat itself,
is less clear. In a recent systematic review of observational studies
(20), the majority of studies suggested that high-fat dairy prod-
ucts were inversely associated with T2D, either significantly or
non-significantly.
In a prospective cohort analysis of the Cardiovascular Health
Study (CHS), trans-palmitoleic acid, a naturally occurring trans
fatty acid found in dairy and ruminant fat, was shown to signif-
icantly and considerably reduce the risk of incident T2D, with
a risk reduction of 62% (21). Dairy fat content appeared to be
directly related to trans-palmitoleic acid levels, and whole-fat but
not low-fat dairy, was also inversely associated with the risk of
T2D. In another subsequent prospective cohort study, the Multi-
Ethnic Study of Atherosclerosis (MESA), trans-palmitoleic acid
was associated with a 48% lower risk of incident T2D (22). A
pooled meta-analysis of these two independent cohorts indicated
a 29% lower incidence of diabetes for each 0.05% point of higher
trans-palmitoleic acid concentrations (22).
SPECIFIC TYPES OF DAIRY PRODUCTS
The evidence regarding the role of specific types of dairy products
such as milk, yogurt, and cheese is limited. Milk has generally
been assessed as part of total dairy consumption, and limited
evidence exists on milk specifically. It appears that milk con-
sumption may be associated with a reduced risk of T2D, with
no association for regular-fat or whole milk and T2D (8, 9, 15).
Limited evidence suggests that yogurt is inversely associated with
T2D (8, 12, 14). Cheese consumption may be associated with a
reduced risk of T2D, but this needs to be confirmed as some
findings are not statistically significant (14–16, 18). Finally, a
protective role of fermented dairy products as a whole (includ-
ing yogurt, cheese, buttermilk, and fermented milk), is suggested
against T2D (14, 18).
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POTENTIAL MECHANISMS
OBESITY ANDWEIGHT
Including dairy products in weight loss diets has been shown
to be favorable by decreasing adiposity, while preserving lean
mass. In a meta-analysis of RCTs, high-dairy calorie-restricted
diets led to a significantly greater reduction in body weight, waist
circumference, and fat mass, while increasing lean mass signifi-
cantly more than conventional weight loss diets (23). In another
meta-analysis, dairy consumption, in the short-term, coupled with
calorie-restriction, had a beneficial impact on body fat reduction
(24). Two systematic reviews of observational studies also showed
that increased dairy consumption may be protective against weight
gain (20, 25).
A large prospective analysis of more than 120,000 individuals
followed for 12–20 years assessed the role of diet (including dairy)
and lifestyle on long-term weight gain and found yogurt to be
a factor associated with a beneficial impact on weight (26). This
study found no association between high-or-low-fat dairy cate-
gories or cheese and weight gain and all liquids, except milk, were
associated with weight gain.
The potential mechanisms by which dairy may be protective
against weight gain include reduced lipogenesis and increased
lipolysis. A high calcium intake may lead to the formation of insol-
uble soaps by calcium and the prevention of fat absorption (24,
27, 28). As well, a systematic review of RCTs has confirmed a role
of calcium in fat oxidation (29). Whey protein may also play a role
in muscle sparing and lipid metabolism (30, 31).
METABOLIC SYNDROME
There is increasing evidence indicating that dairy products may
reduce the risk of MetS including a systematic review of observa-
tional studies (32). The mechanism appears to be via the effects of
different dairy components on specific MetS risk factors, such as
blood glucose level and hypertension, amongst others (32).
DAIRY COMPONENTS
As indicated in Table 2, key dairy components, including cal-
cium, vitamin D, dairy fat, and trans-palmitoleic acid, have been
suggested to contribute to the metabolic pathways that may be
implicated in the prevention of T2D.
CALCIUM
Calcium may play a key role in regulating insulin-mediated intra-
cellular processes in insulin-responsive tissues (10, 33, 34). Insulin
secretion is a calcium-dependent process, and changes in Ca2+
flux can adversely affect the secretory function of pancreatic β-cells
(10). The phosphorylation of insulin receptors is also a calcium-
dependent process (10, 35). Changes in intracellular calcium levels
modulate adipocyte metabolism, which may suppress insulin-
mediated lipolysis and promote de novo lipogenesis, thus leading
to fat accumulation (10, 36).
VITAMIN D
Circulating active vitamin D may have a direct effect on insulin
secretion by binding to vitamin D receptors in pancreatic β-cells.
Vitamin D also has an indirect effect via the regulation of extracel-
lular calcium for normal calcium flux through cell membranes and
adequate Ca2+ pool (37). Vitamin D may enhance insulin receptor
expression and insulin responsiveness for glucose transport (38).
Moreover, vitamin D directly activates peroxisome proliferator
activator receptor-δ, a transcription factor involved in fatty acid
metabolism (39, 40).
T2D has also been shown to be associated with systemic inflam-
mation (41, 42). Insulin sensitivity and β-cell survival may be
improved through the direct effect of vitamin D on the generation
of cytokines (10). Vitamin D also down-regulates genes encoding
pro-inflammatory cytokines involved in insulin resistance (43).
The anti-inflammatory mechanism may also be modulated by the
regulation of Ca2+ levels (10).
DAIRY FAT AND TRANS -PALMITOLEIC ACID
The trans isomer of palmitoleic acid (trans-16:1n-7) is a natural
source of palmitoleic acid, mainly obtained via the diet from dairy
or ruminant fat.Trans-palmitoleic acid may have similar actions to
that of endogenous cis-palmitoleic acid (22, 26). Up-regulation of
adipose-derived cis-palmitoleic acid improves hepatic and periph-
eral insulin resistance, diminishes metabolic dysregulation, and
suppresses hepatic de novo lipogenesis (20, 22, 44). Higher trans-
palimitoleic acids levels are also associated with lower triglycerides,
fasting insulin, blood pressure, and C-reactive protein (21, 22).
Other dairy-derived fatty acids have also been associated with
lower T2D risk but findings are less consistent (22). A recent meta-
analysis of cohort studies has indicated that dietary saturated fat
is not associated with risk of T2D (45).
LIMITATIONS
Our review of the most recent studies on dairy products and risk
of T2D has some limitations. Most of the studies included in this
review consisted of prospective cohort studies. The potential for
bias in such observational studies is present in that individuals who
have a regular consumption of dairy products may also engage in
other healthful diet and exercise behavior. In most studies, adjust-
ments were made for potential confounders, yet, the possibility of
residual confounding cannot be completely eliminated.
CONCLUSION
There is a strong and relatively consistent body of accumulat-
ing evidence indicating that dairy products may significantly
reduce the risk of T2D and likely in a dose-response manner. The
protective effect of low-fat dairy products against T2D appears
consistent in the literature. Evidence on regular-fat dairy prod-
ucts suggests no association with T2D or a beneficial impact. The
role of specific dairy products such as cheese and yogurt appears
beneficial.
IMPLICATIONS FOR FUTURE RESEARCH
More research is needed to better understand the role of regular-
fat and specific types of dairy products on incidence of T2D and
indices of glycemic regulation. Large RCTs are needed to confirm
findings on the role of dairy in the management of cardiometa-
bolic risk factors, particularly in at risk population, such as those
with prediabetes.
Randomized controlled trials are also warranted to increase
our understanding of the role of individual dairy nutrients per se.
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Table 2 | Potential mechanisms of dairy products in preventing type 2 diabetes.
Obesity and weight Favorable effect of dairy products during weight loss through fat mass reduction and preservation/augmentation of lean mass
Reduction of lipogenesis and increase in lipolysis by high calcium intake
Prevention of fat absorption via the formation of calcium insoluble soaps
Increased fat oxidation by calcium
Role of whey protein in muscle sparing and lipid metabolism
Metabolic syndrome Reduced risk of MetS via improvement of several cardiometabolic risk factors (e.g., blood lipids, blood pressure, abdominal fat)
DAIRY COMPONENTS
Calcium Regulation of insulin-mediated intracellular processes in insulin-responsive tissues
Secretory function of pancreatic β-cells
Phosphorylation of insulin receptors
Down-regulation of regulator genes encoding pro-inflammatory cytokines involved in insulin resistance
Vitamin D Direct effect on insulin secretion by binding to vitamin D receptors in pancreatic β-cells
Indirect effect via the regulation of extracellular calcium
Protection against systemic inflammation by counteracting cytokine generation
Trans-palmitoleic acid Improvement of hepatic and peripheral insulin resistance, metabolic regulation, and suppression of hepatic de novo lipogenesis
Lower levels of triglycerides, fasting insulin, blood pressure, and C-reactive protein
Moreover, mechanistic studies are essential to understand the
underlying mechanisms regarding dairy products and specific
dairy components in preventing T2D.
IMPLICATIONS FOR PRACTICE
Given the evidence regarding dairy products in T2D prevention,
translation into practice, and clinical and public health guidance is
warranted. The value of having an adequate intake of dairy prod-
ucts is to be reinforced especially during weight loss and among
those with prediabetes and MetS.
Identifying adequate dairy intake as a key strategy in clinical
practice guidelines for T2D is also needed. Finally, communicat-
ing the importance of meeting dairy recommendations should be
an essential part of public health guidance and identifying strate-
gies to increase dairy consumption to optimal levels is of utmost
importance.
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